-44.8%
ACHR vs MRNA
-4.2%
-40.7%
-90.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -5.7% | -3.4% | -2.3% | -5.3% |
| 7D | -2.7% | -10.1% | +7.4% | -1.4% |
| 30D | -12.1% | +126.7% | -138.9% | -29.7% |
| 3M | +3.4% | +184.1% | -180.7% | -22.4% |
| 6M | -15.6% | +143.3% | -158.9% | -34.4% |
| YTD | -26.9% | +359.9% | -386.7% | -52.1% |
| 1Y | -34.8% | +454.2% | -488.9% | -59.5% |
| 3Y | -19.2% | +26.0% | -45.2% | -34.1% |
| 5Y | -43.8% | -70.3% | +26.5% | -49.7% |
| All | -44.8% | -4.2% | -40.7% | -54.3% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling